Molecularly targeted therapies in adult soft tissue sarcomas: Present approach and future directions

Olivia Aranha, Mark Agulnik*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Background: Sarcomas are rare neoplasms. Given the overwhelming chemotherapy resistance of the disease, patients with progressive and metastatic soft tissue sarcomas are ideal candidates for trials of investigational new drugs. Objective: The authors review the molecular mechanisms underlying soft tissue sarcomas and discuss molecularly targeted therapies developed to improve the poor outcome of these uncommon tumors. Methods: A Medline and American Society of Clinical Oncology abstract search was conducted using the keyword 'soft tissue sarcoma'. Articles and abstracts were reviewed and eligible for inclusion if they used targeted therapies for the treatment of patients with soft tissue sarcomas. Results/conclusion: Phase II clinical trials for patients with soft tissue sarcomas using novel targets and present recognized targets are ongoing and planned.

Original languageEnglish (US)
Pages (from-to)197-207
Number of pages11
JournalExpert Opinion on Therapeutic Targets
Issue number2
StatePublished - Feb 2008
Externally publishedYes


  • Review
  • Soft tissue sarcoma
  • Targeted therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Molecularly targeted therapies in adult soft tissue sarcomas: Present approach and future directions'. Together they form a unique fingerprint.

Cite this